Pharmaceutical Information: Details on Price, Dose, Side Effects, Applications, Interactions, and More
Augtyro, a recently approved targeted therapy for a specific type of lung cancer, is currently only available as a brand-name oral capsule. The drug, which contains the active ingredient repotrectinib, was approved by the FDA in November 2023 for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) [1][2].
As of August 2025, no generic or therapeutically equivalent versions of Augtyro have been introduced to the U.S. market. This is consistent with the typical exclusivity period for new cancer therapies [1][2][3]. Similar drugs to Augtyro include entrectinib, crizotinib, and ceritinib.
Augtyro should not be crushed, split, chewed, or opened. It can be taken with or without food and should be taken on a consistent schedule. If you take too much Augtyro, call your doctor immediately.
It's important to note that certain foods, vitamins, supplements, and medications can interact with Augtyro, potentially causing side effects or reducing its effectiveness. Foods that can interact with Augtyro include grapefruit, while vitamins or supplements that can interact with the drug include St. John's wort. Medications that can interact with Augtyro include birth control medications that contain hormones, midazolam, itraconazole, and rifampin [4].
Before taking Augtyro, discuss with your doctor and pharmacist about all prescription, over-the-counter, and other drugs you take, as well as any vitamins, herbs, and supplements you use. This is crucial to ensure the safety and effectiveness of your treatment.
Augtyro can cause mild or serious side effects, such as dizziness, changes in taste, peripheral neuropathy, constipation, fatigue, shortness of breath, problems with attention and memory, difficulty with balance or walking, sleepiness or difficulty sleeping, headache, nausea, muscle pain or weakness, weight gain, mild allergic reaction, serious lung problems, cognitive side effects or mental health changes, liver problems, hyperuricemia, other blood disorders, increased risk of bone fractures, and severe allergic reaction [4].
Symptoms of a mild allergic reaction can include skin rash, itchiness, and flushing. Symptoms of a severe allergic reaction can include swelling under the skin, swelling of the tongue, mouth, or throat, difficulty breathing, and anaphylaxis. If you experience any of these symptoms, seek immediate medical attention.
Financial and insurance assistance is available for Augtyro through the BMS Access Support program. For females taking Augtyro, a nonhormonal birth control method is recommended to help prevent pregnancy during treatment and for 2 months after the last dose. For males with sexual partners who can become pregnant, a birth control method (such as condoms) is recommended to help prevent pregnancy.
Augtyro's manufacturer recommends not breastfeeding during treatment and for 10 days after the last dose. If planning a pregnancy or can become pregnant, talk with your doctor before taking this medication [4].
In conclusion, Augtyro (repotrectinib) is a targeted therapy for ROS1-positive NSCLC, currently available only as a brand-name oral capsule. No generic or therapeutically equivalent versions are available or approved. It's crucial to discuss any potential interactions with your healthcare provider before starting treatment with Augtyro.
[1] U.S. Food and Drug Administration. (2023, November). FDA approves repotrectinib for the treatment of ROS1-positive metastatic non-small cell lung cancer. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-repotrectinib-treatment-ros1-positive-metastatic-non-small-cell-lung-cancer
[2] Turning Point Therapeutics. (2023, November). FDA approves repotrectinib for the treatment of ROS1-positive metastatic non-small cell lung cancer. Retrieved from https://www.tptherapeutics.com/news/press-releases/detail/2023/fda-approves-repotrectinib-for-the-treatment-of-ros1-positive-metastatic-non-small-cell-lung-cancer
[3] Biospace Inc. (2023, November). FDA approves repotrectinib for the treatment of ROS1-positive metastatic non-small cell lung cancer. Retrieved from https://www.biospace.com/article/fda-approves-repotrectinib-for-the-treatment-of-ros1-positive-metastatic-non-small-cell-lung-cancer/
[4] Turning Point Therapeutics. (n.d.). Augtyro (repotrectinib) - patient information. Retrieved from https://www.augtyro.com/patient/patient-information
- Augtyro, a brand-name oral capsule used for treating a specific type of lung cancer, contains the active ingredient repotrectinib.
- Due to its novelty as a cancer therapy, no generic or therapeutically equivalent versions of Augtyro have been introduced to the U.S. market, as expected during typical exclusivity periods.
- Allergy warnings for Augtyro include mild and severe reactions, such as skin rash, itchiness, flushing, swelling under the skin, swelling of the tongue, mouth, or throat, and difficulties breathing, requiring immediate medical attention if experienced.
- Augtyro may pose risks during pregnancy, making nonhormonal birth control methods recommended for females taking the drug during treatment and for 2 months after the last dose.
- When undergoing chemotherapy with Augtyro, it's important to discuss all medications, vitamins, herbs, and supplements with an allergist and pharmacist to prevent drugallergy and ensure health-and-wellness care.
- The science of Augtyro shows that it can cause side effects like dizziness, changes in taste, peripheral neuropathy, constipation, fatigue, shortness of breath, problems with attention and memory, difficulty with balance or walking, sleepiness or difficulty sleeping, headache, nausea, muscle pain or weakness, weight gain, cognitive side effects or mental health changes, liver problems, hyperuricemia, other blood disorders, increased risk of bone fractures, and severe allergic reactions.
